CASI Pharmaceuticals, Inc. (CASI) EPS Estimated At $-0.03

March 9, 2018 - By Richard Conner

 CASI Pharmaceuticals, Inc. (CASI) EPS Estimated At $ 0.03
Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.53, from 1.67 in 2017Q2. It fall, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported.
Wells Fargo And Co Mn holds 68 shares. Renaissance Technology Limited Liability Company holds 112,900 shares or 0% of its portfolio. Geode Mngmt Ltd Liability Corp has 38,315 shares. Manatuck Hill Prns Ltd Limited Liability Company accumulated 15,090 shares. Vanguard Grp Inc Inc has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Next Fincl Gp has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 2 shares. Wellington Shields Cap Mgmt Limited Liability Corp reported 725,348 shares stake. Wellington Shields & Ltd Liability Company invested 0.29% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Northern Trust reported 31,034 shares. Moreover, Deutsche Bancshares Ag has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 21 shares. Guggenheim Limited Co holds 12,242 shares or 0% of its portfolio. Royal Bank & Trust Of Canada invested in 0% or 17,572 shares. Blackrock reported 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Everett Harris And Ca reported 10,002 shares. Moreover, Jpmorgan Chase & has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI).

Analysts expect CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to report $-0.03 EPS on March, 30.They anticipate $0.02 EPS change or 40.00 % from last quarter’s $-0.05 EPS. After having $-0.03 EPS previously, CASI Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 2.65% or $0.09 during the last trading session, reaching $3.31. About 195,569 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since March 10, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Ratings Coverage

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 5 analyst reports since October 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, October 29 by H.C. Wainwright. Maxim Group maintained CASI Pharmaceuticals, Inc. (NASDAQ:CASI) on Monday, August 14 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $4.5 target in Tuesday, January 16 report. On Thursday, September 22 the stock rating was initiated by Maxim Group with “Buy”.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $231.38 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The company's late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

More notable recent CASI Pharmaceuticals, Inc. (NASDAQ:CASI) news were published by: which released: “CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference” on February 09, 2018, also with their article: “CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio …” published on December 01, 2017, published: “CASI Pharmaceuticals Inc.” on May 15, 2017. More interesting news about CASI Pharmaceuticals, Inc. (NASDAQ:CASI) were released by: and their article: “CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)” published on January 26, 2018 as well as‘s news article titled: “CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By …” with publication date: October 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.